« Cancer Cells: Too Unstable For Fine Targeting? |
| Avastin: Taking It Back »
August 16, 2010
Is Genzyme a Buyable Company At All?
Word is now that Genzyme's manufacturing problems won't be solved for years, which has people wondering if Sanofi-Aventis (or anyone) will feel safe making a bid for them. That's the single biggest issue hanging over the company, and that's an awful lot of uncertainly to be taking on.
If so, it looks more and more like whoever set up this trade will end up doing just fine on it. . .
+ TrackBacks (0) | Category: Business and Markets
POST A COMMENT
- RELATED ENTRIES
- XKCD on Protein Folding
- The 2014 Chemistry Nobel: Beating the Diffraction Limit
- German Pharma, Or What's Left of It
- Sunesis Fails with Vosaroxin
- A New Way to Estimate a Compound's Chances?
- Meinwald Honored
- Molecular Biology Turns Into Chemistry
- Speaking at Northeastern